Antibacterial and antibiofilm activities of zingerone and niosomal zingerone against methicillin-resistant *Staphylococcus aureus* (MRSA)

Laleh Larjianian¹, Morvarid Shafiei², Abdollah Ghasemi Pirbalouti¹, Atousa Ferdousi¹*, Mohsen Chiani³

¹Department of Microbiology, Shahr-e-Qods Branch, Islamic Azad University, Tehran, Iran  
²Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran  
³Department of Nanobiotechnology, Pasteur Institute of Iran, Tehran, Iran

Received: December 2023, Accepted: May 2024

ABSTRACT

Background and Objectives: Methicillin-resistant *Staphylococcus aureus* (MRSA) is a major cause of nosocomial and community acquired infections. Nanoparticles are considered as proper tools to overcome the therapeutic problem of antimicrobial-resistant infections because of the drug concentration increment at the desired location and protection from enzymatic degradation. The goal of this study was to evaluate the effect of the antibacterial and antibiofilm activities of zingerone and niosome containing zingerone against pre-formed biofilm of MRSA isolates.

Materials and Methods: 62 MRSA isolates cultured from patients with diabetic ulcers were investigated. Niosomes were synthesized and characterized by X-ray diffraction, zeta potential and scanning electron microscopy (SEM). The size of niosomal particles measured by SEM and zetasizer.

Results: The surface charge of prepared niosomes was about -37 mV. The effect of the zingerone and niosome containing zingerone was evaluated against biofilms of MRSA isolates. Also, the antibiofilm activity of prepared niosomes on gene expression of MRSA biofilms was evaluated using Real Time PCR. Our results demonstrated that the niosome containing zingerone had a diameter of 196.1 nm and a -37.3-mV zeta potential. Zingerone removed one and three-day old biofilms of MRSA at the concentration of 1000 µg/ml, while the zingerone-laoded niosomes removed 1, 3- and 5-days old biofilms at the concentration of 250 µg/ml, 250 µg/ml, and 300 µg/ml.

Conclusion: The results indicated that niosome containing zingerone eliminated MRSA and its biofilms faster compared with free zingerone and it suggested that zingerone-encapsulated niosomes could be considered as a promising treatment against MRSA and its biofilms.

Keywords: Niosomes; Zingerone; Biofilm; Methicillin resistant *Staphylococcus aureus*

INTRODUCTION

*Staphylococcus aureus* is one of the most common causes of nosocomial infections, bedsores and diabetic wounds. *S. aureus* has become resistant to a extensive range of antibiotics including methicillin, which can be referred to as methicillin-resistant *Staphylococcus aureus* (1). Methicillin-resistant

¹Corresponding authors: Morvarid Shafiei, Ph.D, Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran. Tel: +98-21-64112231 Fax: +98-21-66405535 Email: dr.m.shafiei@pasteur.ac.ir  
Atousa Ferdousi, Ph.D, Department of Microbiology, Shahr-e-Qods Branch, Islamic Azad University, Tehran, Iran. Telefax: +98-21-4689000 Email: atousaferdousi@qodsiau.ac.ir
**ZINGERONE AND NIOSOMAL ZINGERONE AGAINST STAPHYLOCOCCUS AUREUS**

*Staphylococcus aureus* (MRSA) has a chromosomal fragment called staphylococcal cassette chromosome mec (SCCmec). SCCmec has the mecA gene encoding a binding protein with low affinity for penicillin (PBP2a) (2). Biofilm is one of the virulence factors in isolated MRSA, which provide protection against host immune responses and adverse environmental conditions (3). In fact, the ability to form biofilms is a suitable solution for the survival of microorganisms in excessive antimicrobial dosage, resulting to the emergence of resistant infections. This is due to the high resistance of cells within the biofilm to various antimicrobial compounds (4). The capacity of biofilm formation and antibiotic resistance of methicillin-resistant *S. aureus*, have made it a pathogen in the field of health (5). Biofilm production in *S. aureus* bacteria is due to activity of ica ABCD gene. Biofilm production leads to refractory infections, resulting in increased treatment costs and even failures in treatment and recurrence of infections (6). Minimum inhibitory and bactericidal concentrations (MIC and MBC) are standard criteria for antibiotic sensitivity tests and are used as an important reference in the treatment of acute infections (7). Common sensitivity assessment tests are not suitable for evaluation against bacterial biofilms, because free cells are used to determine the amount of MIC, while biofilm cells are more resistant to antibiotics than free cells (8). Niosome nanoparticles are carriers for drug delivery (9). They are a new way of delivering medication into bacterial cells and biofilms and have advantages over liposomes in terms of stability, storage time and better reproducibility than non-ionic surfactants (10). Zingerone is a bioactive compound of ginger root. It is used in the food industry as a flavoring agent (11). Zingerone has different health medicinal benefits, including antibacterial and anti-biofilm (12). In this study, to enhance the antibacterial and antibiofilm activities of zingeron, zingeron loaded niosomes were synthesized. The anti-biofilm and antibacterial activities of niosome containing zingerone and free zingerone were assayed against MRSA clinical strains isolated from diabetic wounds.

**MATERIALS AND METHODS**

**Bacterial isolation and identification.** Specimens were taken from diabetic wound exudates of patients hospitalized at Loghman Hospital in Tehran, Iran using sterile swab technique and transferred to Pasteur Institute of Iran. First, the isolates were diagnosed as *S. aureus* by biochemical tests (13). Also, the susceptibility of isolates to cefoxitin (30 μg) and oxacillin (1 μg) disks was assessed using disk diffusion method according to the Clinical and Laboratory Standard Institute (CLSI) guidelines (14). Notably, *S. aureus* ATCC6538 was used as MRSA controls.

**mecA gene detection.** Bacterial DNA was extracted from cefoxitin-resistant *S. aureus* isolates using a DNA extraction kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The final reaction volume was 25 μl containing 10 μl sterile distilled water, 12 μl of Taq DNA Polymerase Master Mix RED (AMPLIQON, Denmark), 1 μl of forward and reverse meca primers (BIO NEER, Korea), and 1 μl of bacterial DNA Amplification of meca gene, was carried out using GenePro thermal cycler (Bioer Technology, China) with the following cycling program: initial denaturation at 94°C for 4 min, followed by 30 cycles at 94°C for 45 sec, 58.5 °C for 45 sec, and 72°C for 1 min, with a final extension step of 72°C for 3 min (Table 1). PCR products were electrophoresed on 1 % agarose gel, stained with DNA Green Viewer, and visualized using UV transillumination (Alpha Innotech, USA) (13, 14).

**Biofilm formation assay.** Microtiter plate test was used for biofilm formation assay. In Brief, an overnight culture of each isolate was grown in trypticase soy broth plus 0.2% glucose (Merck, Germany) for 24 h at 37°C. The turbidity of growth in this medium was adjusted at 0.5 McFarland opacity using a spectrophotometer (Schimadzu, model UV-120-01, Japan) with the absorbance of 0.08-0.1 at 625 nm. Then, the bacterial suspensions (200 μl) were poured into a 96-well polystyrene microtiter plate (Sigma Aldrich, St. Louis, Missouri, USA) and incubated at 37°C for 24 h without shaking followed by discarding of the supernatants of each well by aspiration. The wells were washed with sterile physiological saline (PBS, pH7.4) to eliminate all unappealing cells. Bacterial cells that adhered to the wells were fixed with absolute methanol for 10 min. The plates were stained with crystal violet (1%W/V). The excess stain was washed in triplicate the bound dye was resolubilized with 200 μl of glacial acetic acid (33%, v/v). The optical density of each well was calculated at 570 nm by ELISA reader. Uninoculated wells containing media were used as control.
Table 1. Minimum Biofilm Eradication Concentration (MBEC) values of zingerone and niosome containing zingerone against one, three and five-day-old biofilms of MRSA isolates.

<table>
<thead>
<tr>
<th></th>
<th>MIC (µg/ml)</th>
<th>Minimum Biofilm Eradication Concentration (MBEC) (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>One-day old</td>
</tr>
<tr>
<td>Zingerone</td>
<td>512 ± 1</td>
<td>1000 ± 1</td>
</tr>
<tr>
<td>Zingerone-loaded niosome</td>
<td>125 ± 1</td>
<td>250 ± 1</td>
</tr>
</tbody>
</table>

Preparation of niosomal zingerone. Thin layer hydration method was used to prepare niosome containing zingerone. First, span 60 (sorbitan monostearate), cholesterol, polyethylene glycol (PEG-3000) (Sigma, USA), and zingerone (Sigma, USA) with a molar ratio of 7:3:1:1 was mixed with 2:1 of a chloroform-methanol solution (16, 17). The control sample was prepared with the same formulation, except zingerone. The final mixture was stirred at 37°C to achieve a homogenized suspension. The niosome suspension was transferred into a round-bottom flask and quietly spun at 100 rpm on a rotary evaporator (WB Eco Laborota 4000 Model, Heidolph Instruments, GmbH) at 60°C to evaporation the organic solvent until a thin lipid film was settled on the wall of the flask. The final solid film was then dried fully by nitrogen gas and resuspended in 20 ml of 1 M phosphate buffer saline (PBS) with a pH value of 7.4, at 60°C. All prepared batches were visually reviewed for opacity and flocculation in clear containers at 4°C (18, 19).

Characterization of niosome: scanning electron microscopy (SEM). SEM (Quanta FEG 450, FEI USA) was employed to evaluate the uniformity, morphology, and size of niosomal zingerone based on the standards at the specialized laboratory of the Tehran University of Technology, Tehran, Iran. The samples were taped to SEM sample stub and coated with a 200 nm gold layer at 0.001 mmHg pressure (millimeters of mercury). Photographs were taken at a convenient magnification (20).

Determination of the particle size, size distribution and zeta potential of niosomal zingerone. Particle size, size distribution and zeta potential of niosome containing zingerone was analyzed using Zeta-sizer instrument (Nano ZS3600, Malvern Instruments Ltd., Worcestershire, UK) mobilized by a 633 nm He-Ne laser. The samples were analyzed at the same temperature, concentration and pH (25°C, 0.1 mg ml⁻¹, pH7.4). The stability of niosomes was monitored for one month at 4°C by measuring the polydispersity index, entrapment efficacy, zeta potential and particle size. The stability of niosomes was monitored during the storage condition (for 1 month at 4°C) by measuring the particle size, polydispersity index, entrapment efficacy, zeta potential.

Zingerone entrapment efficiency. To investigate zingerone entrapment efficacy, followed up according to following (17, 19). Finally, the EE % of zingerone into the niosomal zingerone was determined by the following equation:

\[
EE\% = \frac{\text{amount of initial drug} - \text{amount of unentrapped drug}}{\text{amount of initial drug}} \times 100
\]

Zingerone release. Dialysis method was used to evaluate the release of zingerone from niosome containing zingerone followed up according to following (21).

Fourier transforms infrared spectroscopy (FTIR). Infrared transmission spectra of niosomes were analyzed using a spectrometer (Perkin–Elmer FTIR model 2000) in KBr disks from 4000 to 400 cm⁻¹ (22). FTIR analysis identified absorption bands related to functional groups’ vibrations in free zingerone, niosome containing zingerone and free niosome (as control). FTIR was used to investigate drug-ingredients interaction, compatibility, and structural features of samples (23).

Minimal inhibitory and bactericidal concentrations (MIC and MBC). The MIC and MBC of zing-
erone and zingerone-loaded niosomes against MRSA isolates were determined using the microtiter plate method according to CLSI standards (24).

Biofilm dispersion assay. A microtiter plate assay was used to determine the biofilm dispersion (21, 25). 20 µl of serially diluted bacterial suspension (1.5 x 10^7 CFU/mL) was applied to each well of sterile 96-well microtiter plates containing 180 µl of TSB medium. The plates were incubated for one day, three days and five days at 37°C. Then, 200 µl of PBS (pH 7.4) was used to wash off the non-adherent cells (26). Various dilutions of zingerone suspension and noisomal zingerone suspension were added to the wells. Blank niosome and medium alone (TSB + 0.1% of glucose) were used as negative control group. Three replicates were considered for each concentration. The plates were washed three times with PBS, and crystal violet (CV) was used to dye the biofilms. The absorbance was measured at 570 nm using an automatic ELISA reader (Titertek, R Multiscan, Germany) (27, 28).

Gene expression examination by real-time PCR.
In order to analyse the effect of the zingerone and niosomes containing zingerone on MRSA biofilms, the expression levels of the ica A and ica D genes in MRSA (ATCC 6538) were assessed by real-time PCR (3, 29).

RNA extraction and cDNA synthesis. Extraction of RNA from biofilms was performed with RNX-Plus kit according to the manufacture instruction (SinaColon Co. Iran). Then, synthesis of cDNA was carried out with cDNA synthesis Kit (Zist Fanavaran Co. Iran) (3, 29).

Real-time PCR performance. Quantitative real-time PCR was applied in a Light Cycler 96 Instrument with Roche Applied Science (Penzberg, Germany) with a SYBR Green kit (ABI, USA). All reaction tubes contained 2 µl of the cDNA, 0.5 µl of each of the forward and reverse primers, 10 µl SYBR green PCR master mix and 7 µl DEPC water. The reaction was started with an initial denaturation at 95°C for 5 min and 40 amplification cycles of 94°C for 20s, 60°C to 62°C (annealing temperature of icaA, icaD and 16S rRNA were 62°C, 60°C and 60°C, respectively) for 20 sec and 72°C for 20 sec. The formula \( RQ = 2^{-\Delta\Delta CT} \) was used to get relative gene expression in the comparative CT method and 16S rRNA was used as an internal control (3, 29).

Statistical analysis. One-way and two-way analysis of variance were used for statistical analysis (ANOVA) (Tukey test) (IBM SPSS Statistics 26.0.0.1 FP001 IF007) and Log-rank test for survival analysis by GraphPad Prism v. 9.0 software with a statistically significant p-value < 0.05.

Ethical approval. This study was approved by the Pasteur Institute of Iran ethics committee (IR.PII.REC.1400.086).

RESULTS

Isolation of MRSA. 98 of 160 clinical isolates were identified as S. aureus, according to the phenotypic and biochemical tests and 62 isolates were diagnosed as MRSA according to the results of anti-biogram tests and meca gene PCR amplification.

Investigation of niosome properties. Based on the micrograph obtained from SEM, the niosome nanoparticles were spherical and almost identical in size. The size of niosomal particles measured by scanning electron microscopy was about 160 nm and the diameter measured by the zetasizer was about 196 nm (Fig. 1). Size distribution of niosome nanoparticles showed homogeneous dispersion for particles. Surface charge of niosome containing zingerone was about -37 mV. No significant difference was found in size, zeta potential, PDI and morphology between niosome containing zingerone and its control (zingerone free niosome).

Zingerone entrapment efficiency. The EE % of synthesized niosomes was obtained from an indirect method and using the zingerone standard curve equation. The results of our study demonstrated that EE% of niosome containing zingerone was about 69 %.

In vitro release study. Our results showed that around 75% of zingerone (non-niosomal form or standard form) is released from dialysis bag after 15 hours, but only 30% of zingerone is released from the niosomal carrier after 36 hours. Comparative release of free zingeron and niosomal zingerone showed that zingerone in niosomal form is released at a slower rate than free zingerone (Fig. 2).
Fig. 1. SEM micrograph (left) and size distribution curve (right) of zingerone-loaded niosomes obtained by the dynamic light scattering method.

Fig. 2. Comparison of the release of zingerone from niosome and free zingerone at 37°C.

Fourier transform infrared spectroscopy. The spectra recorded for niosome with and without zingerone showed similar typical bands, indicating the characteristics in the backbone structure of the different substrates. It can be seen multiple complex absorption bands for zingerone in 457.27-1469.00 cm⁻¹ because the molecular structure contains benzene ring. These bands are characteristics peaks related to zingerone. In addition, the wide peak in 3444.64 cm⁻¹ was due to the hydroxyl group in the structure of zingerone. In the B pattern in (Fig. 3), a wide with medium intensity peak was observed in the 3435.54 cm⁻¹ which is the characteristic hydroxyl groups in the niosome structure and similar band was observed in the C pattern 3422.64 cm⁻¹ for niosome containing zingerone with preserving its structure. Also, sharp bands were observed in the 1737.17 cm⁻¹ and 1576.28 cm⁻¹ for stretching vibration of C=O functional groups in the niosome with and without zingerone, respectively. Relative wide peaks at 3435.54 cm⁻¹ and 3422.64 cm⁻¹ due to the hydroxyl group related to cholesterol in the niosome structure was also observed in B and C patterns, respectively (30). Slight changes in the spectra were observed in Pattern C, the peaks related to niosome containing zingerone when compared with the control of niosome (without zingerone in Pattern B). As can be seen, in pattern C, peaks at 2919.80, 1736.22, and 2850.44 cm⁻¹ when the drug was introduced into the niosome, were slightly changed to 2919.19, 1737.17, and 2850.10 cm⁻¹, respectively. It can be concluded that between niosome and drug did not occur chemical interaction, and both have kept their nature and stayed away from change. It showed that zingerone had been entrapped in the niosome and had kept its nature.

The MIC and MBC of zingerone and niosome containing zingerone. As demonstrated in (Table 1), the MIC and MBC of niosome containing zingerone were 125 µg ml⁻¹ and 250 µg ml⁻¹, respectively while the MIC and MBC of zingerone against MRSA strains were 512 µg ml⁻¹ and 1000 µg ml⁻¹, respectively.

Minimum biofilm eradication concentration (MBEC). The free zingerone and zingerone-loaded niosomes eradicated one-day old biofilm at the concentrations of 1000 and 250 µg ml⁻¹, respectively (Table 1). Free zingerone (at × 2 MIC) affected on one-day old biofilm mass, however, niosome contain-
Fig. 3. FTIR spectra (A) free zingerone, (B) niosome without zingerone as control, (C) niosomes containing zingerone.
ing zingerone had substantial effect on one day old MRSA biofilm (P < 0.05). Free zingerone at 1000 µg ml⁻¹ eliminated three-days old preestablished biofilm, whereas, niosome containing zingerone affected one three- and five-days old biofilms at concentrations of 250 µg ml⁻¹ and 500 µg ml⁻¹, respectively. However, free Zingerone did not significantly affect five-day old biofilm mass. The eradication rate of zingerone and niosome containing zingerone against one, three- and five-days old MRSA biofilms is demonstrated (Fig. 4).

According to our results, zingerone-loaded niosomes eradicated 90%, 70% and 55% of one, three- and five-day old MRSA biofilm.

Effect of zingerone and zingerone-loaded niosomes on the expression levels of biofilm-associated genes quantified by real-time PCR. Real-time PCR results indicated that in the presence of zingerone-loaded niosomes, the expression of the biofilm-associated genes (ica A and ica D) reduced significantly (Fig. 5, P < 0.001). However, compared to the positive control, zingerone-loaded niosomes had a 50% reduction in the expressions of ica A and ica D genes (Fig. 5, P ≤ 0.01).

**DISCUSSION**

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a considerable public health problem worldwide, causing significant morbidity and mortality and also raising healthcare expenses (31). MRSA incidence has increased over the last 10 years and is a public health problem in healthcare facilities, sports facilities, clinics, and the community. In recent year, MRSA was known as a high-priority pathogen, causing drastic challenges in healthcare systems (32, 33). The biofilm formation ability of staphylococci has for decades been identified as the most frequent cause of biofilm-associated infections with *S. epidermidis* and *S. aureus* and is closely associated to genetic lineages, multidrug-resistance profiles, and highly virulent strains (31). Our results indicated that MRSA isolates have a high ability for biofilm formation, which has a significant role in decemment of resistant and recurrent infections.

Nanoparticles are considered as a suitable and promising drug delivery system to control the formation of microcolonies and biofilms. Niosomes as lipid nanoparticles are known as drug carriers for various reasons including controlling and slowing
drug release, protecting pharmaceutical molecules, small size, ability to cross bio barriers, increasing drug shelf life and being biodegradable and non-toxic. In this study, niosomes were well-organized with morphologically spherical with a mean particle size of 196 nm. It is indicated that the small size of niosomal particles enhanced antibacterial activity (34, 35). Zingerone with the formula 4-(4-hydroxy-3-methyl phenyl) butane is one of the active compounds of ginger root which is used in the food industry as a flavoring and seasoning and also is a natural, herbal, and non-toxic compound (36). Due to the development of resistant bacteria to almost all existent antibiotics (37), the use of natural compounds such as zingerone can be a promising solution for the treatment of chronic infections caused by MRSA biofilm.

According to the results of the current study, niosome containing zingerone had a spherical morphology with an average diameter of 196.1 nm. It is indicated that the smaller size of nanoparticles leads to more effective antibacterial activity (38). Additionally, the zeta potential of -37.3 mV implied high stability of our noisome containing zingerone because the absolute zeta potential of 30 mV and higher showed more stability and appropriate dispersion due to electrostatic repulsion (39). Despite the small size of our niosome, the percentage of zingerone entrapment in the primary noisome containing zingerone batch was calculated at 69.1%. This high entrapment efficiency can result from its formulation containing span60 and cholesterol. It is proven that the entrapment efficiency is considerably affected by the type and amount of surfactant as well as the surfactant/cholesterol ratio (40). The length of the alkyl chain of used surfactants is a significant factor affecting the permeability of niosomes for zingerone entrapment and consequently on their antimicrobial effectiveness (42).

In the present study, niosomes containing zingerone compared to free zingerone, significantly affected the pre-formed biofilm of MRSA isolates. The amount of zingerone MIC was drastically reduced when encapsulated in niosomes. In 2014, Barakat et al. (41) investigated the effect of niosomes containing vancomycin on the inhibition of S. aureus biofilm. They stated that using niosomes as nano carriers is a new approach to inhibit the formation of S. aureus biofilm. In 2020, Kashef et al. (43), investigated the antimicrobial and anti-biofilm activity of niosomes containing ciprofloxacin against 59 clinical S. aureus isolates. The results revealed that in more than 62% of isolates, MBIC and MBEC niosome form of ciprofloxacin compared to free ciprofloxacin decreased. In 2021, Zafari et al. (18) investigated the anti-biofilm activity of niosomes containing ceftazolin against MRSA strains. The in vitro results showed that niosomes containing ceftazolin were significantly removed one, three- and five-day old MRSA biofilms. The results of the present study confirmed the results of the researches that we mentioned and in addition, provided a new idea and strategy for the treatment of infections associated with MRSA biofilms, especially in the treatment of diabetic wounds. Therefore, using Niosomal Zingerone can be a promising solution for the treatment of chronic infections caused by MRSA biofilm.

CONCLUSION

Zingerone-loaded niosomes offer an alternative approach to the treatment of human biofilm-associated infections. To our knowledge, this is the first report on the eradication of MRSA formed biofilms by Zingerone-loaded niosomes. Further investigations will be necessary to assess the safety and efficacy of the niosomes for a potential application in clinical trials.

REFERENCES

(ica) in clinical Staphylococcus aureus isolates. GMS Hyg Infect Control 2013; 8: Doc03.
6. Gad GF, El-Feky MA, El-Rehewy MS, Hassan MA, Abollela H, El-Baky RM. Detection of icaA, icaD genes and biofilm production by Staphylococcus au-
7. Vallet I, Olson JW, Lory S, Lazdunski A, Fillion A. The chaperone/usher pathways of Pseudomonas aerugin-
10. Aparajay P, Dev A. Functionalized niosomes as a smart delivery device in cancer and fungal infection. Eur J
Pharm Sci 2022; 168: 106052.
11. Ahmad B, Rehman MU, Amin I, Ahmad SB, Farooq A, Muzamil S, et al. Zingerone (4-(4-hydroxy-3-methyl-
phenyl)butan-2-one) protects against alloxan-induced diabetes via alleviation of oxidative stress and in-
prehensive and mechanistic review. Toxicol 2023; 233: 107247.
13. Seth AK, Geringer MR, Nguyen KT, Agnew SP, Du-
AN. Overview of changes to the clinical and laboratory standards institute performance standards for antim-
icrobial susceptibility testing, M100, 31st Edition. J Clin
Microbiol 2021; 59(12): e0021321.
15. Shafiei M, Abdi Ali A, Shahcheraghfi F, Saboora A, Akbari Noghabi K. Eradication of Pseudomonas aera-
17. Antunes BP, Moreira AF, Gaspar VM, Correia IJ. Chi-
19. Shamkani F, Barzi SM, Badmasti F, Chiani M, Mirab-
BL6 mouse pneumonia model. Int Immunopharmacol 2023; 115: 109551.
20. Jacob S, Nair AB, Al-Dhibbi BE. Preparation and eval-
uation of niosome gel containing acyclovir for en-
hanced dermal deposition. J Liposome Res 2017; 27:
283-292.
89: 52-66.
23. Faghizadeh F, Anaya NM, Schifman LA, Oyaned-
el-Craver V. Fourier transform infrared spectroscopy to assess molecular-level changes in microorganisms exposed to nanoparticles. Nanotechnol Environ Eng 2016;
1: 1-16.
24. Wiegand I, Hilpert K, Hancock RE. Agar and broth
dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat
25. Robertson J, McGoverin C, White JR, vanholstbeek F,
Swift S. Rapid detection of Escherichia coli antibiot-
26. Thammarshawan S, Sirirotsguk P, Nasompag S, Dad-
Sci 2021; 8: 177.
27. Gopalakrishnan S, Gupta A, Makabenta JMV, Park J,
Mater 2022; 11(21): e2201060.
29. Atshan SS, Shamsudin MN, Karunananthi A, Van Bel-
36. Ahmad B, Rehman MU, Amin I, Arif A, Rasool S, Bhat SA, et al. A review on pharmacological properties of zingerone (4-(4-Hydroxy-3-methoxyphenyl)-2-buta-